Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11145285 | 0.88 | GRIA1 (0.37) | GRIA1HSD17B10ALDH1A1 | |
| SCHEMBL28387464 | 0.85 | GRIA1 (0.36) | GRIA1 | |
| SCHEMBL28096531 | 0.81 | CA1 (0.39) | GRIA1MAPT | |
| SCHEMBL23926322 | 0.81 | MEN1 (0.34) | GRIA1MEN1KMT2A | |
| SCHEMBL11520683 | 0.80 | — | — | |
| SCHEMBL148567 | 0.79 | GABRR1 (0.33) | GRIA1 | |
| SCHEMBL28977313 | 0.79 | ANPEP (0.32) | GRIA1KMT2A | |
| SCHEMBL19583223 | 0.79 | PTGS1 (0.33) | GRIA1 | |
| SCHEMBL11142806 | 0.78 | LMNA (0.35) | GRIA1HSD17B10SLC6A4MEN1USP2 | |
| SCHEMBL11667830 | 0.77 | TP53 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0169074-A2 | Treatment of subterranean formations | HALLIBURTON COMPANY (US) | 1986-01-22 | — | — | EP | claimed |
| JP-6220386-A | — | — | None | — | — | JP | disclosed |
| CN-106104268-B | Lithium reagent composition uses the lithium ion measuring method and measurement device for having the composition | 梅托珍尼克斯株式会社 | 2019-06-07 | — | — | CN | disclosed |
| CN-105368426-B | Parents' head base anion surfactant and preparation method thereof | 中国石油化工股份有限公司 | 2018-08-17 | — | — | CN | disclosed |
| CN-106590569-A | Enhanced oil extraction method with improved recovery efficiency | 中国石油化工股份有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106590588-A | Tertiary oil recovery oil displacement composition and preparation method thereof | 中国石油化工股份有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106104268-A | Lithium reagent composition, use have lithium ion assay method and the determinator of said composition | 梅托珍尼克斯株式会社 | 2016-11-09 | — | — | CN | disclosed |
| CN-105368426-A | Double hydrophilic head-based anionic surfactant and preparation method thereof | CHINA PETROLEUM & CHEM CORP | 2016-03-02 | — | — | CN | disclosed |
| US-7858661-B2 | Protein refolding agent and refolding method | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1988936-A1 | METHOD FOR STERILIZATION OF HYDROGEL CONTACT LENSES | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007098040-A1 | METHOD FOR STERILIZATION OF HYDROGEL CONTACT LENSES | NOVARTIS AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-5462590-A | Stable pH during storage | FUJI XEROX CO., LTD. (JP) | 1995-10-31 | — | — | US | disclosed |
| JP-H06220386-A | INK FOR INK JET AND RECORDING METHOD USING THE SAME | FUJI XEROX CO LTD | 1994-08-09 | — | — | JP | disclosed |
| US-4368287-A | POLYESTER CONTAINING AMINO-SULFONIC AMPHOIONIC GROUP | NIPPON PAINT CO., LTD. (JP) | 1983-01-11 | — | — | US | disclosed |
| US-4328143-A | Aqueous coating composition | NIPPON PAINT COMPANY, LTD. (JP) | 1982-05-04 | — | — | US | disclosed |
| US-4322324-A | Ampho-ionic group-containing alkyd resins | NIPPON PAINT CO., LTD. (JP) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | GRIA1 3867/4885HSD17B10 1128/4885SLC6A4 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.